PDSB
PDS BiotechnologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
A successful VERSATILE-003 restart could improve the regulatory timeline and reduce development burden, while PDS01ADC provides additional oncology optionality [#SEC-8K-2026-05-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Early ADC data come from small cohorts and require follow-up validation.
Momentum
78
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.75 · Bear $0.30
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum78 · Δ7d -
Value41 · Δ7d -0.1
Sentiment69 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
78
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
69
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 77.5 / Value 41.1 / Sentiment 69.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$41.1M
Beta
1.19
Shares Out
55.92M
P/E (TTM) · Derived
-1.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.56
Rev YoY
-
EPS YoY
-36.8%
Gross Margin
-
Op Margin
-
Net Debt
-$9.79M
Current Ratio
2.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology